Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6571405 | 0.74 | RAPGEF4 (0.43) | RAPGEF4CA1CA2MMP1MMP2 | |
| Water SCHEMBL28948684 | 0.68 | RAPGEF4 (0.33) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL9116079 | 0.67 | CA1 (0.42) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL1047352 | 0.66 | RAPGEF4 (0.39) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL9682715 | 0.65 | RAPGEF4 (0.41) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL11420240 | 0.65 | RAPGEF4 (0.43) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL242786 | 0.65 | RAPGEF4 (0.43) | RAPGEF4ALDH1A1KMT2AMAPT | |
| Phosphine SCHEMBL22634061 | 0.63 | RAPGEF4 (0.41) | RAPGEF4ALDH1A1KMT2AMAPT | |
| SCHEMBL10798387 | 0.63 | RAPGEF4 (0.41) | RAPGEF4ALDH1A1KMT2AMAPT | |
| SCHEMBL129762 | 0.63 | ACHE (0.57) | RAPGEF4ALDH1A1KMT2AMAPTF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106164073-A | Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | 赛诺菲 | 2016-11-23 | — | — | CN | disclosed |
| US-9221807-B2 | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| US-20150239875-A1 | SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239875-A1 | SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, EPX | RAPGEF4 2514/4885CA1 4543/4885CA2 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.